Biosimilars Business Roundup For August 2023—Podcast Edition

On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.

On this episode, we’re going to be giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.

Show Notes

FDA Approves First MS Biosimilar

Stelara and Enbrel Chosen for IRA Price Negotiation

Biocon Biosimilar Quarterly Sales Up 106%

STADA Earnings Project Record Breaking Profits for 2023

Despite Global Increase in Amjevita Sales, US Sales Dropped 63%

Authors Suggest Major Policy Shifts to Boost Biosimilar Development, Accessibility

Cardinal Health Exec: How Adalimumab Biosimilars Can Reshape the US Health Care Industry